Kornimate/medical-research-clean huggingface dataset:
efficacy of pegylated interferon on liver fibrosis in co-infected patient with hiv and hepatitis c

Conditions: HIV Infections; Hepatitis C, Chronic

Summary: the aim of this study is to prove the efficacy of peginterferon in hiv infected patients with liver disease caused by hepatitis c virus (hcv) when the treatment to eradicate the virus failed. this scientific proof needs a comparative study to be done including two groups of patients randomly allocated: one with the treatment (peginterferon) and the other without any treatment against hcv with a duration of 2 years. to conclude, two liver biopsies are needed; one before the study and a second 2 years after.

c hepatitis in hiv infected patient becomes a major issue although the survival of patients, has improved in the last decades regarding to the advent of haart, the mortality related to liver disease has increased in this population. sustained virological response for hcv can be obtained with peg-interferon and ribavirin treatment but more or less 50% of patients experienced failure to this treatment and liver fibrosis due to hcv infection progress and may lead to cirrhosis and hepato-carcinoma. to demonstrate the efficacy of peginterferon therapy to reduce the liver damage causes by hcv infection, a randomised controlled study is needed comparing one group of patient treated by peginterferon and one group without any treatment against hcv infection. in order to show 30% difference between the two groups in reducing one point of fibrosis score (metavir scale), 150 patients are needed. the duration of the study is 96 weeks

Eligibility criteria:
inclusion criteria: * hiv infection (western blot +) * c hepatitis (rna viral hepatitis c \[vhc\] +) * chronic active c hepatitis on liver histological score metavir (a over or equal to 1 and f over or equal to 2) on biopsy performed at least 18 months before the expected date of inclusion * previous treatment for c hepatitis for at least 3 months including peg-interferon and ribavirin or peg-interferon alone if counterindication for ribavirin occurred * failure to eradicate c hepatitis virus after well conducted treatment * the liver biopsy should have been realised at least 18 months before inclusion : either before treatment for c hepatitis in patients treated at most 7 months or at least 6 months after anti hcv treatment in patient treated for more than 7 months (wash out period) * regular follow up in an outpatient clinic for hiv * unchanged antiretroviral treatment the last 3 months before inclusion * inform consent exclusion criteria: * history of transplantation or clinical hepatic failure * opportunistic infection in the past three months before inclusion * any hepatic disease not related to hcv (b hepatitis, hemochromatosis, wilson disease) * diabetes mellitus * immunocompromised treatment * active intravenous drug addiction * alcohol consumption of more than 50 g per day * counterindication for the use of interferon

Keywords: hiv infections peginterferon alfa-2a treatment failure hepatitis c, chronic treatment experienced
efficacy comparison between different management strategies for consistent oab in patients with svms after surgery

Conditions: Spinal Vascular Disorder Nos; Overactive Bladder

Summary: the investigators' goal is to compare the efficacy of three different management strategies (sacral neuromodulation, botulinum toxin, m receptor antagonist) in treating consistent oab in patients with svms after surgery.

spinal vascular malformations (svms) are complex neurosurgical lesions and account for 3%-4% of all intradural spinal cord mass lesions, which can influence the function of bladder. the investigators' goal is to compare the efficacy of three different management strategies (sacral neuromodulation, botulinum toxin, m receptor antagonist) in treating consistent oab (overactive bladder) in patients with svms after surgery.

Eligibility criteria:
inclusion criteria: * •patient diagnosed with spinal vascular diseases including intradural arteriovenous malformation,intradural arteriovenous fistula,dural arteriovenous fistula,extradural arteriovenous malformation,paravertebral arteriovenous malformation,paravertebral arteriovenous fistula,cobbs' syndrome,and other spinal arteriovenous metameric syndromes involve the spinal cord. * patient not received surgical or interventional treatment before * patient with normal cardiac, renal and hepatic function * patient capable of understanding the content of the patient information / informed consent form * patient willing and able to participate in the registry * patients have consistent oab after surgery exclusion criteria: * •patient received surgical treatment or interventional treatment before * patient is pregnant * patient allergic to iodine * patient unable to complete follow-up * patient with cerebral lesions * patient with other spinal lesions * patient with cardiac, renal or hepatic dysfunction

Keywords: spinal vascular disorder overactive bladder
collection of gastrointestinal tissue samples for the characterization and ex vivo functional assessment of chemoreceptors

Conditions: Diabetes

Summary: the purpose of this study is to help scientists understand how the gut senses ingested nutrients and what kind of processes take place for their absorption in order to establish the association with diabetes and other metabolic diseases scientists need human specimens to study.


Eligibility criteria:
inclusion criteria: 1. men and women age 18 years and older who are having elective gastrointestinal surgery 2. able to provide written, informed consent exclusion criteria: 1. unable to provide written, informed consent 2. use of antibiotics for more than 5 consecutive days in the three months prior to the study

Keywords: metabolic diseases
laparoscopic vs open bilateral inguinal hernia repair

Conditions: Inguinal Hernia Bilateral

Summary: the european hernia society guidelines of 2018 suggest that laparoscopic surgery should be preferred over open surgery for bilateral inguinal hernia repair even though scientific evidence are scarce. we will conduct a prospective, non randomise control trial, to investigate the superiority of one technique over the other.


Eligibility criteria:
inclusion criteria: * bilateral inguinal hernia exclusion criteria: * american society of anaesthesiology score \>3 * complicated inguinal hernias

Keywords: bilateral inguinal hernia repair
multiplexing prism fitting for field expansion of monocular vision

Conditions: One Eye Blindness; Blind Left Eye; Blind Right Eye

Summary: the investigators are developing an assistive device, known as multiplexing prism that expands the field of view for individuals with acquired monocular vision (loss of an eye). the investigators are testing a simplified design and fitting protocol to provide field expansion for individuals with acquired monocular vision.


Eligibility criteria:
inclusion criteria: * no medical health issues such as seizures, motor movements problem * loss of vision in one eye (less than 20/200) for \>1 year) * visual acuity of the seeing eye: better than 20/32 visual acuity with correction * no visual field defect in the seeing eye (nasal field of at least \>45degree) * no medical health issues such as seizures, motor movements problem exclusion criteria: * patients with any physical or mental disabilities, including cognitive dysfunction, balance problems, or other deficits that could impair their ability to respond to the stimuli presented in this study will be excluded * any person with motor movements problem (e.g., unable to use extremities)

Keywords: field expansion collision detection walking response time
causes and characteristics of occupational eye injuries in western turkey

Conditions: Other and Unspecified Superficial Injuries of Eye

Summary: patients with work-related eye injuries (wrei) admitted to the center in the four-year period were enrolled in this prospective study. institutional review board approval was obtained before commencement of the study. a special data recording system was developed for the study. the study sample comprised only the casualties occurred at workplace and while working de facto. the data were abstracted via face to face contact in the emergency department (ed). the data sheets comprised sociodemographic and injury-related information brought together in 15-item questionnaire. causes of occupational injuries as reported by the victims were assigned to either of two groups: "worker-related causes" and "workplace-related causes". since workers are known to be pressured by the workplace to work in unsafe ways, an isolated room in the ed was used for this purpose in order to prevent bias and the patients were not accompanied by any person other than the medical personnel in charge of due medical care. the patients were also assured that the information obtained by the survey are to be used for research purposes only and no feedback is to be given to employers or related persons. patients who did not give consent for the study, fatal accidents and patients younger than 15 years of age were excluded from the analysis.

all data obtained in the study were recorded in and analyzed using the statistical package for social sciences for windows, version 17. numerical variables were given as mean and standard deviation (sd), while categorical variables were given as frequencies (n) and percentages.

Eligibility criteria:
inclusion criteria: * the study sample comprised only the casualties occurred at workplace and while working de facto exclusion criteria: * other
the development of path, a program to support nicu parent mental health through the transition from hospital to home

Conditions: Perinatal Mental Health

Summary: the objective of this study is to develop and pilot test a telehealth-based mental health screening and engagement program that supports parents as their infants transition home from the nicu. the program will use a stepped-care approach to screen parents for depression, anxiety, and ptsd; provide a brief behavioral intervention to those who screen as having at least a low risk of these conditions; and provide a warm hand-off to community mental health services for those at medium to high risk.


Eligibility criteria:
inclusion criteria: * nicu parents: participants will be parents of currently hospitalized preterm infants from either the ohsu nicu or the uch nicu. we will include parents of live preterm infants who have been admitted in the nicu for at least 2 weeks. parents must speak english or spanish. parents can be of any age. * nicu stakeholders: participants will be stakeholders from either the ohsu nicu or the uch nicu. stakeholders will be social workers, mental health providers responsible for providing more intensive mental health support for nicu parents, nurses, neonatologists, and hospital administrators.

Keywords: neonatal intensive care unit perinatal mental health perinatal depression perinatal anxiety posttraumatic stress disorder
laboratory study of cancer & immune cells in ascites fluid of ovarian cancer patients to test alternative therapies

Conditions: Ovarian Cancer

Summary: ascites samples from women undergoing surgery for ovarian cancer will be collected for use in translational research.

the purpose of this study is to collect ascites fluid obtained from ovarian cancer patients during cytoreductive surgery or paracentesis at the university of new mexico hospital or cancer center. cancer cells and immune cells from the ascites fluid will be used to test novel immunotherapies for ovarian cancer treatment and to establish patient derived xenograft models to perform preclinical testing on a cancer cell population that better models the heterogeneity in patient disease

Eligibility criteria:
inclusion criteria: * all female participants, regardless of ethnicity, who are undergoing cytoreductive surgery for ovarian cancer are eligible for this study * all participants will be eighteen years old or older * patients must be suspected of having a pathological diagnosis or clinical suspicion of ovarian cancer and be scheduled for surgery for tumor resection. * ability to understand and the willingness to sign a written informed consent document. * pathologic confirmation of a diagnosis of epithelial adenocarcinoma of the ovary, fallopian tube, or primary peritoneal cancer (serous, mucinous, clear cell, endometrioid, undifferentiated, mixed, transitional cell) * women of childbearing potential must have a negative qualitative serum pregnancy test ≤ 2 weeks prior to study entry. * a female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * has not undergone a hysterectomy or bilateral oophorectomy; or * has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). exclusion criteria: * we do not intend to include participants if they are unable to provide informed consent for this study themselves (e.g. mentally ill patients who require health care proxies to consent for any medical intervention), or vulnerable populations such as prisoners. * minors under age eighteen. * pregnant women. * final pathologic diagnosis that does not confirm invasive epithelial ovarian, tubal, or primary peritoneal cancer

Keywords: ovarian cancer ascites
exploring the benefit of topical capsaicin in treating pain from chemo-induced peripheral neuropathy: a longitudinal single center pilot study

Conditions: Peripheral Neuropathy Due to Chemotherapy

Summary: to learn if topical capsaicin can help relieve pain from cipn and improve gait (the pattern of walking) in patients.

primary objectives • to assess changes in gait (specifically looking at velocity) before and after use of topical capsaicin. secondary objectives * to assess pain intensity numerical rating scale (nrs) scores in chemotherapy induced peripheral neuropathy (cipn) participants before and after use of capsaicin 8% topical patch. * to assess changes in quantitative sensory testing (qst) before and after use of topical capsaicin. * to assess skin punch biopsy to compare the integrity of epidermal nerve fibers and meissner's corpuscles (mc) in cipn patients before and after use of topical capsaicin (optional). * to assess pain tumor related neuropathy assessment scale (tnas) before and after topical capsaicin * to assess pain interference using the brief pain inventory (bpi), before and after topical capsaicin * to assess patient global impression of change (pgic) * to assess the rate of adverse events and tolerability of topical capsaicin as reported by participants

Eligibility criteria:
inclusion criteria: * participants diagnosed with pain of the lower extremity from chronic (\>90 days duration) cipn (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds), seen at md anderson cancer center * participants reporting baseline pain ≥ 4 (0-10 scale, nrs) * participants age 18+ * participants who have completed chemotherapy within the last year at the time of enrollment. exclusion criteria: * participants with cognitive dysfunction * participants with recent history (\<6 months) of drug or alcohol abuse * participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection * participants with allergies to capsaicin or adhesives * pregnant participants
18f-dopa pet imaging: an evaluation of biodistribution and safety

Conditions: Congenital Hyperinsulinism; Neuroblastoma; Neuroendocrine Tumors; Parkinson Disease; Brain Glioma

Summary: single centre prospective cohort phase iii study of 18f-dopa pet/ct imaging in specific patient populations: 1. pediatric patients with congenital hyperinsulinism 2. pediatric patients with neuroblastoma 3. pediatric or adult patients with suspected extra-pancreatic neuroendocrine tumor 4. adult patients with a clinical suspicion of parkinson's disease 5. pediatric or adult patients with primary brain tumors this study will evaluate the biodistribution and safety of 18f-dopa produced at the edmonton pet centre.


Eligibility criteria:
inclusion criteria: * 1. pediatric patients (less than 17 years old) with congenital hyperinsulinism * 2. pediatric patients (less than 17 years old) with neuroblastoma * 3. pediatric patients (less than 17 years old) or adult patients (17 or older) with known or clinically suspected neuroendocrine tumor outside of the pancreas * 4. adult patients (17 or older) with a clinical suspicion of parkinson's disease. * 5. pediatric (less than 17 years old) or adult patients (17 or older) with primary brain tumors exclusion criteria: * unable to obtain consent * weight \> 250 kg (weight limitation of pet/ct scanner) * adult patients unable to lie flat for 20-30 minutes to complete the pet/ct scan * young pediatric patients (less than 10 years old) who are unable to lie flat for 20-30 minutes and for whom clinical sedation is contraindicated (as determined by a pediatric anaesthesiologist) * pregnancy * lack of intravenous access

Keywords: 18f-dopa pet/ct
influence of propofol on alveolar macrophage in asthmatic patients

Conditions: Asthma

Summary: the change of airway responsiveness and alveolar macrophage (am) immunity occurs during the pathogenesis of asthma. macrophage-associated airway protection in patients with asthma is affected positively or negatively by propofol general anesthesia. the investigators hypothesized that the effects of propofol on asthmatic ams and corresponding airway reactivity in vivo is different from the in vitro research. through in vivo airway hyperresponsiveness (ahr) observation and clinical investigation of am immune functions from asthma patients undergoing propofol general anesthesia to clarify the precise effects of propofol on am immunity, and to provide theoretical basis for the clinical administration of propofol in asthmatic patients. this would optimize the practice of clinical anesthesia, especially for those with the tendency of ahr.


Eligibility criteria:
inclusion criteria: * asa physical status i-ii; * aged from 18 years to 45 years; * patients with or without asthma or a history record of asthma; * undergoing elective lumpectomy under general anesthesia. exclusion criteria: * allergy to propofol and opioids, a history of the use of centrally-acting drugs of any sort, chronic pain and psychiatric diseases records; * participants younger than 18yr，older than 45yr or pregnancy; * those who were not willing to or could not finish the whole study at any time; * the pacu assessing score was under 6 on a scale of 10 (measuring somnolence, respiration, movement, color, and blood pressure on 0-2 scales), and arterial oxygen saturation measured by pulse oximetry (sao2) was 92% or lower (supplemental oxygen was permitted).

Keywords: general anesthesia propofol immunity alveolar macrophages
video-based intervention in reducing anxiety in patients undergoing lung cancer screening

Conditions: Anxiety; No Evidence of Disease; Lung Carcinoma

Summary: this pilot trial studies a video-based intervention in reducing anxiety in patients undergoing lung cancer screening. giving a video-based intervention to patients prior to lung cancer screening may reduce anxiety and improve the well-being and quality of life.

primary objectives: i. test the feasibility and acceptability of the video-based intervention. secondary objectives: i. to describe incidence, degree, and duration of screen-related anxiety among individuals scheduled to undergo low-dose computed tomography (ct) scan (ldct) for lung cancer screening (lcs). ii. to describe baseline patient characteristics and pre-screening anxiety levels. iii. to describe the preliminary outcomes on screen-related anxiety for patients both not in the intervention group and those in the intervention group. outline: patients are assigned to 1 of 2 groups. group i: patients receive standard of care following lcs consisting of routine visits and telephone contact with the lcs program nurse practitioner and coordinator. group ii: patients undergo a video-based intervention prior to undergoing lcs. patients watch a 5-minute video that focuses on preparing patients for lcs by providing information on the following: program team and contact information; reason to be screened; screening eligibility; how screening is performed; what to expect on the day of screening; what to expect after screening; what to expect if result is positive; what to expect if result is negative; and risks of screening. patients also receive an educational handbook. patients with positive scans (a lung-imaging reporting and data systems \[rads\] 3 or 4) receive additional brochure and nursing support within 1 week after notification of scan results. after completion of lcs, patients are followed up at 1 week and then at 3 and 7 months.

Eligibility criteria:
inclusion criteria: * this study will be conducted in people scheduled to undergo baseline ldct as part of the city of hope (coh) lcs program * there are no restrictions related to performance status and life expectancy * all subjects must have the ability to understand and the willingness to participate in the informed consent process, although a waiver of written informed consent is obtained for this study exclusion criteria: * patients who do not speak or read, because all intervention materials, including the video and written materials are in english * subjects, who in the opinion of the investigator, may not be able to comply with study procedures
the impact of vitamin d on disease activity in crohn's disease

Conditions: Crohn Disease

Summary: the purpose for this study is to determine the effect of vitamin d supplementation on disease activity in crohn's disease patients in canada and saudi arabia

hypothesis 1: patients who are suffering from crohn's disease are at risk of vitamin d deficiency. to determine vitamin d status and disease activity in crohn's disease cases in canada and saudi arabia. hypothesis 2: providing vitamin d in doses higher than rda (recommended dietary allowance) reduces disease activity in crohn's disease cases. to evaluate the impact vitamin d in doses higher than rda (recommended dietary allowance) on disease activity in crohn's disease patients.

Eligibility criteria:
inclusion criteria: * newly diagnosis with an active crohn's disease, * age above of 16 years exclusion criteria: * remission or the duration of disease is more than 2 years, * pregnancy, * liver or kidney failure, * inability to take oral supplements or medicine

Keywords: vitamin d crohn disease disease activity inflammation prevention